Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Milestone payments
View:
Post by lscfa on Apr 05, 2024 6:12pm

Milestone payments

With R+F it was $50,000 US, then another $50,000 US.  Abbvie has paid $500,000 US so is the next payment $500,000 US too?  Timing?
Comment by forhandlaren on Apr 05, 2024 7:33pm
Do you remember that management ensured us that the previous PP would be the final one? But they just offered and partly closed another one. Do you remember the Q&A where Howard elaborated about how much time between deal and product launch - and referred to R+F 18 months as standard? I think Abbvie planned the product launch for this January, but for some reason it's delayed. I'm ...more  
Comment by moneycollector on Apr 06, 2024 3:29am
Two comments on this: I don't know how many times Sirona's management has said that this was the last PP... I also don't know how many statements HV has made that have turned out to be complete nonsense. The now complete inexistence of any residual credibility in the two cardboard figures in Vancouver is reflected in the share price.  And if the actual case were to occur that ...more  
Comment by tylerreddick on Apr 06, 2024 7:53am
I think Howie's first mistake was teaming up with a two-bit company like Rodan and Fields, allowing them to string us along while they did absolutely nothing with 1067. That hurt our credibility a lot. Allergen is a whole different ballgame, as they wouldn't have bothered with us if they didn't see some potential there. But they are  like a massive iceberg, slow to get going but ...more  
Comment by biorun on Apr 06, 2024 3:05pm
Sounds logical - I would hope the milestone would come in advance of launch, if Howard was thinking straight - that way we could at least see something show up on the financials in advance and give something back to the blissfully ignorant situation we continue to tolerate.
Comment by BurningMoney5 on Apr 06, 2024 3:42pm
This post has been removed in accordance with Community Policy
Comment by biorun on Apr 06, 2024 5:00pm
Sounds to me you make your money off of fear mongering and bottom feeding. 
Comment by Fruckedagain on Apr 07, 2024 10:58am
Biorun. Sounds to me you make your money on Bulship pumping. No matter what, I'm FRUCKEDAGAIN bi howie.
Comment by tylerreddick on Apr 07, 2024 5:41pm
I doubt biorun makes any money.
Comment by MirrorWorldMan on Apr 07, 2024 11:25pm
Imagine instantly losing 35% of your money in a private placement. Howie is addicted to dilution and now we all suffer. Where was this dedication to increase shareholder value? Lets see the AbbVie deal specifics.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities